viewAmphion Innovations PLC

Amphion Innovations CEO buys 65,000 more shares


Amphion Innovations (LSE: AMP) told investors that its chief executive Richard Morgan has increased his stake in the company, purchasing 50,000 shares at 15p per share and 15,000 at 16p. Consequently, Morgan now owns approximately 23.7 million shares representing 17.967% of Amphion’s issued share capital.

Earlier this month, Amphion released positive results for the year ended 31 December 2009. Amphion increased revenues by 22% to US$8.6m, subsequently gross profits increased almost 70% to US$5.8m.

The specialist investment and commercialisation company narrowed operating losses to US$892,937 during the year, compared to a US$3.4m loss in 2008.

For the full-year, reported Net Asset Value (NAV) per Share was US $0.42, compared to US$0.44 in the previous financial year. Additionally, Amphion said it should be noted that its intellectual property assets, which are valued at amortised cost, are producing sizable levels of gross income, which the company believes will continue in the future and could lead to an increase in value.

Amphion builds shareholder value in high growth companies in the medical and technology sectors by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.  Currently there are eight partner companies developing proven technologies targeting substantial commercial marketplaces in excess of US$1 billion.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amphion Innovations PLC named herein, including the promotion by the Company of Amphion Innovations PLC in any Content on the Site, the Company...


Amphion Innovations pinning hopes on Polarean Inc after Motif Bio success

Richard Morgan, chief executive of Amphion PLC (LON:AMP), discusses the 'very welcome' Phase III Iclaprim news from Motif Bio. Motif's recently revealed its lead drug, a next generation antibiotic, successfully negotiated a crucial final-stage clinical study, boosting Amphion’s...

on 10/10/17

2 min read